Clinical value of serum complement component 7 and apolipoprotein C-Ⅱ in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiotherapy
Objective To investigate the clinical value of serum complement component 7(C7)and apolipoprotein C-Ⅱ(ApoC-Ⅱ)in the follow-up of patients with locally advanced cervical squamous cell carcinoma(CSCC)treated with radiotherapy.Methods A total of 104 patients with locally advanced CSCC who received radiotherapy or concurrent chemoradiotherapy in Cangzhou People's Hospital from May 2018 to January 2020 were selected as the study objects.Serum C7 and ApoC-Ⅱ levels were detected by enzyme-linked immunosorbent assay(ELISA).Disease-free survival(DFS)was recorded after 1 month of follow-up after radiotherapy.The area under the curve(AUC)of receiver operating characteristic(ROC)curve was used to analyze the prognostic value of serum C7 and ApoC-Ⅱ levels.The prognostic factors were analyzed by univariate and multifactorial Cox proportional regression models.Kaplan-Meier method was used to draw the survival curve and Log-Rank test was performed.Results The predictive value of serum C7 and APC-Ⅱ combined detection was higher,with an AUC of 0.938(95％CI:0.888-0.987).There was no significant correlation between serum C7 and clinicopathological features(P＞0.05).High levels of serum ApoC-Ⅱ were associated with larger tumor diameter(P＜0.05).Tumor diameter,serum C7 and ApoC-Ⅱ were independent factors affecting the prognosis of DFS in patients with locally advanced CSCC(P＜0.05).A molecular risk model was constructed based on C7 and ApoC-Ⅱ,and the combined model risk score was an independent prognostic factor for DFS in CSCC patients(P＜0.001).Kaplan-Meier survival curves showed that the DFS rates of high-risk and low/medium risk patients were 13.3％and 89.2％,respectively,and the median DFS time was 287 days and 858 days,respectively(P＜0.001).Conclusions Decreased levels of serum C7 and ApoC-Ⅱ are significantly associated with poor prognosis in patients with locally advanced CSCC,suggesting that they are potential biomarkers for predicting radiotherapy prognosis in patients with locally advanced CSCC.
万方数据
维普
